Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Pro-NETU (fosnetupitant) for prevention of HEC-induced nausea and vomiting
jRCT2080223300Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Aug 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fosnetupitant in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Started Aug 2016; status: completed.
02
Drugs
fosnetupitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT2080223300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223300.